Suven Life Sciences has obtained four product patents, two each from China and Korea. These correspond to the new chemical entities (NCEs) for the treatment of disorders connected to the brain functions.
The patents would be valid through 2025 and 2027, respectively, said the Hyderabad-based company.
With these patents, Suven has a total of five granted patents from China and seven from Korea. The company is developing therapeutic agents which would be useful in the treatment of diseases like Alzheimer’s, Parkinson, Schizophrenia and attention deficient hyperactivity disorder, a release said.
Mr Venkat Jasti, CEO of Suven, said: “Suven is developing a pipeline of molecules in the central nervous system (CNS) area to meet the demands to treat disorders like the above with an estimated market potential of $30 billion globally.”
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.